SEC Form 4 · accession 0001209191-17-053301
Cidara Therapeutics, Inc. · CDTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc Wilson
Officer — Chief Accounting Officer
Period of report
Sep 18, 2017
Accepted (ET)
Sep 19, 2017 · 4:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610618
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 18, 2017 | A | 5,000 | $0.00 | A | 10,356 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF3,F4 | — | Sep 18, 2017 | M | 10,000 | A | — | — | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F11/3rd of the total number of shares subject to the restricted stock unit shall vest on each December 31 of 2018, 2019 and 2020.
- F2Includes 1,414, 1,603, 350, and 1,989 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2015, May 20, 2016, November 18, 2016 and May 19, 2017, respectively.
- F3Restricted stock units convert into common stock on a one-for-one basis.
- F4A portion of the shares vest upon the achievement of various clinical and corporate milestones.